We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Others suggest a bunch f small deals, noting BIIBI has a better record of value creation from their smaller deals. So I don't follow much in the SMID euro space, except for Minerva (NERV) and Intra-Cellular Therapies (ITCI). If they get a good readout later this year, that could potentially put them in play. There are, of course many more to choose from in the SMID range. It's just even harder to pick ones of any quality.
A research note I'm seeing says BIIB has 18 billion for M&A.
In an interview on CNBC, a Jefferies analyst said that Biogen ( BIIB-29.5%) may now be targeting acquisitions after its aducanumab flop. Attractive candidates include Biohaven Pharmaceutical Holding Company ( BHVN+8.2%), Neurocrine Biosciences ( NBIX+5.9%), Alder BioPharmaceuticals ( ALDR+6.2%), Sage Therapeutics ( SAGE+3.6%), ACADIA Pharmaceuticals ( ACAD+3.7%) and GW Pharmaceuticals ( GWPH+3.3%).
A Stifel analyst agreed, adding that Sarepta Therapeutics ( SRPT+2.1%) could be a target as well.